Showing 8091-8100 of 10543 results for "".
- Analysis: PRS Improves Melanoma Risk Predictionhttps://practicaldermatology.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a
- BPO Not Linked with Higher Malignancy Risk: Meta-analysishttps://practicaldermatology.com/news/bpo-not-linked-with-higher-malignancy-risk-meta-analysis/2486846/Benzoyl peroxide (BPO) use for acne vulgaris was not significantly associated with increased malignancy risk in a systematic review and meta-analysis of more than 4 million patients, accoriding to results from a new meta-analysis.
- Imaging Bests Exam in Detecting Nodal Metastases in High-Risk cSCChttps://practicaldermatology.com/news/imaging-bests-exam-in-detecting-nodal-metastases-in-high-risk-cscc/2486802/Ultrasonography and computed tomography (CT) outperformed physical examination for detecting baseline nodal metastases in high-risk cutaneous squamous cell carcinoma (cSCC). Investigators for the prospective, multicenter diagnostic study evaluated baseline staging modalities for detecting
- IEC Establishes Global Definitions for AD Disease Control and Remissionhttps://practicaldermatology.com/news/iec-establishes-global-definitions-for-ad-disease-control-and-remission/2486652/A new consensus statement from the International Eczema Council (IEC) proposes standardized definitions for low disease activity (LDA), very low disease activity (vLDA), and remission in atopic dermatitis (AD), addressing what authors noted as a longstanding gap in
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th
- Nicotinamide Linked to Reduced Melanoma Risk in VA Cohorthttps://practicaldermatology.com/news/nicotinamide-linked-to-reduced-melanoma-risk-in-va-cohort/2486445/Nicotinamide exposure was associated with a 25% reduction in melanoma incidence in a large VA cohort, according to data from a retrospective cohort study presented at the 2026 American Academy of Dermatology Annual Meeting. Investigators analyzed 30,741 pati
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- Litifilimab Advances CLE Treatment With Positive Phase 2 Datahttps://practicaldermatology.com/news/litifilimab-advances-cle-treatment-with-positive-phase-2-data/2486419/Late-breaking data from the Phase 2 AMETHYST Part A trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting show that litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), improved disease activity in patients with cutaneous lupus erythemato
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.